Health Condition 1: N189- Chronic kidney disease, unspecified
Conditions
Interventions
Intervention1: Cholecalciferol: Doses 300000IU
Frequency: twice( at day 0 and at week 16)
Route: oral
Therapy Duration: 8 week
Control Intervention1: NA: NA
Sponsors
Indian Council of Medical Research
Eligibility
Inclusion criteria
Inclusion criteria: 1. Age 18-75 years 2. eGFR by CKD-EPI 15-60 ml/min/1.73m2 3. Serum 25(OH)D levels 4. Clinically stable course as judged by the treating physician for last 3 months
Exclusion criteria
Exclusion criteria: 1. Heart failure, 2. present or past malignancy 3. Pregnancy in case of female 4. Vitamin D supplementation within the past 30 days 5. Receiving long-term maintenance dialysis 6. Receiving immunosuppressive therapy 7. Diagnosis of chronic liver disease, 8. Diagnosis of primary hyperparathyroidism 9. Diagnosis of sarcoidosis
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Change in immune function parameters at 16 weeks (TH1, TH2,Th17,Treg and CD4+CD28null cells) with cholecalciferol supplementation in patients with Stage 3-4 CKDTimepoint: 16 week | — |
Secondary
| Measure | Time frame |
|---|---|
| Change in endothelial function (FMD, e-Selectin, ICAM, VCAM) Change in vascular function (PWV) Change in inflammatory markers(IFN- ?, TNF-a IL-1ß, IL-6, IL-17, IL-23 IL-4, IL-10, and IL-13) Timepoint: 16 weeks | — |
Countries
India
Contacts
Public ContactAshok Kumar Yadav
Postgraduate Institute of Medical Education and Research
Outcome results
None listed